"The U.S. Food and Drug Administration today approved the Argus II Retinal Prosthesis System, the first implanted device to treat adult patients with advanced retinitis pigmentosa (RP). The device, which includes a small video camera, transmitter "...
DOSAGE AND ADMINISTRATION
If signs and symptoms fail to improve after two days, the patient should be re-evaluated (see PRECAUTIONS).
The dosing of FML FORTE® (fluorometholone ophthalmic suspension 0.25%) suspension may be reduced, but care should be taken not to discontinue therapy prematurely. In chronic conditions, withdrawal of treatment should be carried out by gradually decreasing the frequency of applications.
FML FORTE® (fluorometholone ophthalmic suspension, USP) 0.25% is supplied sterile in opaque white LDPE plastic bottles with droppers with white high impact polystyrene (HIPS) caps as follows:
10 mL in 15 mL bottle - NDC 11980-228-10
5 mL in 10 mL bottle - NDC 11980-228-05
15 mL in 15 mL bottle - NDC 11980-228-15
Note: Store at or below 25°C (77°F); protect from freezing. Shake well before using.
Revised June 2004. Allergan Inc. Irvine, CA 92612, U.S.A. FDA Rev date: 01/10/06
Last reviewed on RxList: 7/30/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional FML Forte Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.